Article

Study Finds Low-Dose Aspirin Can Reduce the Risk of Pancreatic Cancer

The longer a person took low-dose aspirin, the lower his or her risk for developing pancreatic cancer, according to a study published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

The longer a person took low-dose aspirin, the lower his or her risk for developing pancreatic cancer, according to a study published in

, a journal of the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention

“We found that the use of low-dose aspirin was associated with cutting the risk of pancreatic cancer in half, with some evidence that the longer low-dose aspirin was used, the lower the risk,” said

, professor of epidemiology in the Department of Chronic Disease Epidemiology at the

and Yale Cancer Center in New Haven, Connecticut. “Because about one in 60 adults will get pancreatic cancer and the five-year survival rate is less than 5 percent, it is crucial to find ways to prevent this disease.”

Harvey A. Risch, MD, PhDYale School of Public Health

Men and women who took low-dose aspirin regularly had 48 percent reduction in their risk for developing pancreatic cancer. Protection against pancreatic cancer ranged from 39 percent reduction in risk for those who took low-dose aspirin for six years or less, to 60 percent reduction in risk for those who took low-dose aspirin for more than 10 years.

Press release:

http://bit.ly/1myASMW

Source: AACR

Related Videos
Kara Kelly, MD, chair of pediatrics, Roswell Park Oishei Children's Cancer and Blood Disorders Program
Sandra Cuellar, PharmD
Wanmei Ou, PhD, vice president of product, data analytics, and AI at Ontada
Glenn Balasky, executive director of the Rocky Mountain Cancer Center.
Corey McEwen, PharmD, MS
dr linda bosserman
dr andrew leitner
Glenn Balasky during a video interview
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo